NRx Pharmaceuticals (NASDAQ:NRXP) Raised to Hold at Zacks Research

NRx Pharmaceuticals (NASDAQ:NRXP) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other research firms also recently weighed in on NRXP. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. BTIG Research reaffirmed a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Wednesday, February 18th. Ascendiant Capital Markets reissued a “buy” rating and issued a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. HC Wainwright increased their price target on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, NRx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

NRx Pharmaceuticals Stock Down 0.3%

NRx Pharmaceuticals stock opened at $1.80 on Monday. The business has a 50 day moving average price of $2.12 and a two-hundred day moving average price of $2.51. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84. The stock has a market cap of $57.37 million, a price-to-earnings ratio of -0.77 and a beta of 1.97.

Institutional Trading of NRx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP increased its holdings in shares of NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares in the last quarter. Geode Capital Management LLC grew its position in NRx Pharmaceuticals by 17.8% during the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after acquiring an additional 33,004 shares during the last quarter. Commonwealth Equity Services LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter valued at $994,000. State Street Corp raised its position in NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Anson Funds Management LP raised its position in NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after purchasing an additional 1,018,853 shares during the last quarter. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.